Pacific Biosciences has raised $30m through an underwritten public offering of 12.5 million shares of its common stock priced at $2.4 a share.
The underwriters will be granted an option to purchase an additional 1.875 million shares within 30 days of the offer closure.
The funds are intended to be used for working capital and other general corporate purposes, including the acquisition of or investment in other businesses and technologies.
Based in the US, Pacific Biosciences is involved in the manufacturing and marketing of integrated platforms for genetic analysis.
The company appointed Professional Corporation as the legal advisor for the offering.
The funds are intended to be used to develop existing facilities at the site, including two cleanrooms for the production of medical implants.
The UK-based translational genomics and molecular diagnostics company plans to use the funds to conduct global clinical programmes and commercially launch its ColoScape cancer screening technology.
GeneMatrix Inc has raised KRW3.5bn ($3.2m) through the private placement of third tranche unregistered and unsecured private convertible bonds.
Based in South Korea, GeneMatrix Inc is a developer of platform and molecular diagnostics products.
The agreement also grants Roche the worldwide distribution rights to the NGAL test incorporated with its analysers.
Based in Denmark, BioPorto is an in-vitro diagnostics company, while Roche Diagnostics is a diagnostic solutions provider based in the US.
The collaboration will increase the availability of NGAL tests and establish them as a diagnostic marker for kidney injury.
Akers Biosciences Inc has raised $2.13m through the private placement of 11.3 million shares of its common stock priced at $0.187 a share.
Based in the US, Akers is a rapid screening and testing products manufacturer.
The company appointed finnCap as the legal advisor for the transaction.
Biom’Up SAS plans to raise €18m ($22.19m) through a public offering of 1.6 million new shares priced at $11 a share.
If the option to increase the issue size is exercised, the proceeds are expected to increase to €20.7m ($25.52m).
The company plans to use the funds to boost production capacity and to open a second production plant to meet the demand for its haemostatic product HEMOBLAST Bellows.
Biom’Up has simultaneously raised €25m ($30.82m) through the private placement of bonds with stock warrants.
Based in France, Biom’Up is a developer of medical devices based on patent-protected biopolymers.